Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Lumos Diagnostics has secured a $41.38/test reimbursement rate for its FebriDx diagnostic test from the Centers for Medicare and Medicaid Services, effective January 2025. The approval is expected to enhance accessibility and adoption of FebriDx, which helps differentiate between bacterial and viral infections, addressing antibiotic resistance concerns. This milestone is seen as a significant step in the U.S. commercialization strategy for Lumos’ innovative diagnostic solutions.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.